Search
Veverimer
go.drugbank.com/drugs/DB18977InvestigationalVeverimer is under investigation in clinical trial NCT03390842 (Long-term Safety Extension to Study TRCA-301).
Propionate ion
go.drugbank.com/drugs/DB19384InvestigationalPropionate ion is under investigation in clinical trial NCT00846326 (Preventing Tolerance to Oxymetazoline in Allergic Rhinitis).
Clorindione
go.drugbank.com/drugs/DB13275ExperimentalClorindione is a vitamin K antagonist, which may be useful to decrease prothrombin levels in humans.
Alcuronium
go.drugbank.com/drugs/DB13648ExperimentalA non-depolarizing skeletal muscle relaxant similar to [tubocurarine]. It is used as an anesthesia adjuvant.
Rolicyclidine
go.drugbank.com/drugs/DB01549ExperimentalIllicitBecause of its pharmacodynamic similarity to the drug phencyclidine (PCP), rolicyclidine was added to the Schedule I list of illegal drugs in the USA in the 1970s.
Nitroarginine
go.drugbank.com/drugs/DB04223InvestigationalAn inhibitor of nitric oxide synthetase which has been shown to prevent glutamate toxicity. … Nitroarginine has been experimentally tested for its ability to prevent ammonia toxicity and ammonia-induced alterations in brain energy and ammonia metabolites. (Neurochem Res 1995:200(4):451-6)
Elsulfavirine
go.drugbank.com/drugs/DB14929InvestigationalElsulfavirine is under investigation in clinical trial NCT03706898 (Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food
Dexpramipexole
go.drugbank.com/drugs/DB15130InvestigationalFrom the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)). … Dexpramipexole is under investigation in clinical trial NCT01511029 (Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured
Metenkefalin
go.drugbank.com/drugs/DB12668Investigational[A203225] It has been shown to reduce chromosomal abberations in patients with multiple sclerosis. … [A203210] Metenkefalin, along with [tridecactide], are under investigation as an immunomodulatory therapy for moderate to severe COVID-19.[L13874,L13877]
PYM50018
go.drugbank.com/drugs/DB05126ExperimentalWhen administered orally to a transgenic pre-clinical model of ALS, PYM50018 delays the loss of muscle strength and extends survival time. … In pre-clinical models, PYM50018 has been observed to protect against neuronal damage, increase neurite outgrowth, reverse oxidative damage and reverse neuronal apoptosis in vitro.